Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
Aleksandra Sobolewska-Włodarczyk,1 Marcin Włodarczyk,1 Martin Storr,2 Jakub Fichna1 1Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland; 2Center of Endoscopy, Starnberg, Germany Abstract: Diarrhea-predominant irritable bowel syndrome (IBS-D) belongs to the grou...
Saved in:
Main Authors: | Sobolewska-Włodarczyk A (Author), Włodarczyk M (Author), Storr M (Author), Fichna J (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2016-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
by: Özdener AE, et al.
Published: (2017) -
Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives
by: Liu R, et al.
Published: (2020) -
Serum-derived bovine immunoglobulin for children with diarrhea-predominant irritable bowel syndrome
by: Arrouk R, et al.
Published: (2018) -
Eluxadoline Versus Antispasmodics in the Treatment of Irritable Bowel Syndrome: An Adjusted Indirect Treatment Comparison Meta-analysis
by: Di Qin, et al.
Published: (2022) -
Eluxadoline-Loaded Eudragit Nanoparticles for Irritable Bowel Syndrome with Diarrhea: Formulation, Optimization Using Box-Behnken Design, and Anti-Diarrheal Activity
by: Md. Khalid Anwer, et al.
Published: (2023)